KOD Share Price | Kodiak Sciences, Inc. Stock Analysis & Recommendation

Q: Is Kodiak Sciences, Inc. technically bullish or bearish?

As of 13 August 2025, the technical trend for Kodiak Sciences, Inc. has changed from mildly bullish to bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the daily moving averages also support this bullish outlook. The KST is bullish on both weekly and monthly time frames. However, the RSI shows no signal on both weekly and monthly charts, and the Dow Theory indicates no trend. In terms of performance, Kodiak has significantly outperformed the S&P 500 over the past year with a return of 269.92% compared to the S&P 500's 17.14%, but it has lagged behind in the shorter time frames, such as the year-to-date return of -1.11% versus the S&P 500's 12.22%. Overall, the current technical stance is bullish, supported by multiple indicators, though recent short-term performance has been weak.

Q: How big is Kodiak Sciences, Inc.?

Market Cap: As of Jun 18, Kodiak Sciences, Inc. has a market capitalization of 187.31 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, Kodiak Sciences reported net sales of 0.00 million and a net profit of -190.63 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 150.29 million and total assets of 335.58 million.

Q: What does Kodiak Sciences, Inc. do?

Overview:Kodiak Sciences, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics to treat ophthalmic diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -57 Million (Quarterly Results - Mar 2025) Market cap: USD 187.31 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.26 Return on Equity: -173.39% Price to Book: 1.72 Contact Details:Address: 1200 PAGE MILL RD, PALO ALTO CA: 94304 Tel: 1 650 2810850 Website: https://kodiak.com/

Q: Who are in the management team of Kodiak Sciences, Inc.?

As of March 2022, the management team of Kodiak Sciences, Inc. includes Dr. Victor Perlroth, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Mr. Robert Profusek holds the position of Lead Independent Director. The board also features several independent directors: Dr. Felix Baker, Mr. Charles Bancroft, Dr. Bassil Dahiyat, and Dr. Richard Levy.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

392.31 k

Shareholding (Mar 2026)

FII

4.01%

Held by 70 FIIs

DII

93.57%

Held by 22 DIIs

Promoter

2.42%

Is Kodiak Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 13, 2025, Kodiak Sciences, Inc. shows a bullish technical trend supported by MACD, Bollinger Bands, and moving averages, despite recent short-term underperformance compared to the S&P 500.

View full answer

How big is Kodiak Sciences, Inc.?

22-Jun-2025

As of Jun 18, Kodiak Sciences, Inc. has a market capitalization of 187.31 million, with net sales of 0.00 million and a net profit of -190.63 million for the latest four quarters. The company reported shareholder's funds of 150.29 million and total assets of 335.58 million as of December 2024.

View full answer

What does Kodiak Sciences, Inc. do?

22-Jun-2025

Kodiak Sciences, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for ophthalmic diseases. It has a market cap of $187.31 million and reported a net profit loss of $57 million as of March 2025.

View full answer

Who are in the management team of Kodiak Sciences, Inc.?

22-Jun-2025

As of March 2022, Kodiak Sciences, Inc.'s management team includes Dr. Victor Perlroth as Chairman, President, and CEO, with Mr. Robert Profusek as Lead Independent Director and several independent directors including Dr. Felix Baker, Mr. Charles Bancroft, Dr. Bassil Dahiyat, and Dr. Richard Levy.

View full answer

Compare Kodiak Sciences, Inc. with Similar Stocks

CARA Therapeutics, Inc.Bionano Genomics, Inc.IO Biotech, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,259 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.68

Return on Equity

-909.32%

Price to Book

95.34

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-58 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

49.73%

6 Months

32.41%

1 Year

905.92%

2 Years

1227.51%

3 Years

296.78%

4 Years

351.45%

5 Years

-57.01%

Kodiak Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-163.07%

EBIT to Interest (avg)

-234.55

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.26

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

95.34

EV to EBIT

-10.39

EV to EBITDA

-11.80

EV to Capital Employed

36.25

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-348.88%

ROE (Latest)

-909.32%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 42 Schemes (15.11%)

Foreign Institutions

Held by 70 Foreign Institutions (4.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -1.22% vs -33.72% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-53.40",
          "val2": "-50.40",
          "chgp": "-5.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.20",
          "val2": "-57.50",
          "chgp": "-1.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -30.53% vs 32.36% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-206.20",
          "val2": "-160.10",
          "chgp": "-28.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-230.00",
          "val2": "-176.20",
          "chgp": "-30.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-53.40

-50.40

-5.95%

Interest

0.00

Exceptional Items

0.00

-1.90

100.00%

Consolidate Net Profit

-58.20

-57.50

-1.22%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -1.22% vs -33.72% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-206.20

-160.10

-28.79%

Interest

0.00

Exceptional Items

-1.90

0.00

Consolidate Net Profit

-230.00

-176.20

-30.53%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -30.53% vs 32.36% in Dec 2024

All Annual Results

Company CV

About Kodiak Sciences, Inc.

Kodiak Sciences, Inc.

Pharmaceuticals & Biotechnology

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.

Company Coordinates

Company Details

1200 PAGE MILL RD , PALO ALTO CA : 94304

Tel: 1 650 2810850

https://kodiak.com/

Registrar Details